Why the study?
Does sorafenib increase mortality in the setting of myocardial infarction?
Does sorafenib increase mortality in the setting of myocardial infarction?
Sorafenib exacerbates cardiac damage and dramatically increases mortality post-myocardial infarction by inducing myocyte necrosis and impairing endogenous stem cell-mediated repair.
May warrant caution with sorafenib post-MI; leaves open human translation and need for clinical studies.
Sorafenib cardiotoxicity results from myocyte necrosis rather than from any direct effect on myocyte function. Surviving myocytes undergo pathological hypertrophy. Inhibition of c-kit+ stem cell proliferation by inducing apoptosis exacerbates damage by decreasing endogenous cardiac repair. In the setting of MI, which also causes large-scale cell loss, sorafenib cardiotoxicity dramatically increases mortality.
No takes yet. Share an insight, caveat, or question.
Duran et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: